Compare HLX & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | ABCL |
|---|---|---|
| Founded | 1979 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.3M | 1.1B |
| IPO Year | 1997 | 2020 |
| Metric | HLX | ABCL |
|---|---|---|
| Price | $7.11 | $4.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $10.50 | $7.75 |
| AVG Volume (30 Days) | 1.5M | ★ 4.5M |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 497.36 | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,312,445,000.00 | $35,325,000.00 |
| Revenue This Year | N/A | $25.45 |
| Revenue Next Year | $4.96 | $10.07 |
| P/E Ratio | $25.10 | ★ N/A |
| Revenue Growth | N/A | ★ 7.17 |
| 52 Week Low | $5.52 | $1.89 |
| 52 Week High | $9.18 | $6.52 |
| Indicator | HLX | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 57.61 | 55.48 |
| Support Level | $6.15 | $4.08 |
| Resistance Level | $7.47 | $4.66 |
| Average True Range (ATR) | 0.21 | 0.27 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 72.28 | 57.58 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. the Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.